Evolution of the Average Target: IDEXX Laboratories, Inc.

Evolution of the Target Price: IDEXX Laboratories, Inc.

Changes in Analyst Recommendations: IDEXX Laboratories, Inc.

5fc091148335cf361.EHYzblN53M7V2-HkUJY0GKe25ZvObsiMY-K7zFSfDX0.dA51FDdBvfrsq6qqNedGYdTskf_5H7K0BprZlCf2axkgGwMrZS6OiKy30Q~2fde2d5daab73ab6fedaeb1e990663b3
Aug. 11 Barclays Adjusts Price Target on IDEXX Laboratories to $710 From $800, Keeps Overweight Rating MT
Aug. 05 Jefferies Adjusts Price Target on IDEXX Laboratories to $795 From $792 MT
Aug. 05 Citigroup Adjusts Price Target on IDEXX Laboratories to $670 From $650 MT
Aug. 05 UBS Adjusts Price Target on IDEXX Laboratories to $670 From $620, Maintains Neutral Rating MT
Jul. 27 Elanco Seems Best-Positioned Into Q2 Print Among Animal Health Stocks, UBS Says MT
Jul. 27 UBS Cuts IDEXX Laboratories Price Target to $620 From $640, Maintains Neutral Rating MT
Jul. 13 Leerink Partners Adjusts IDEXX Laboratories Price Target to $715 From $725, Maintains Outperform Rating MT
May. 06 Rothschild & Co Redburn Adjusts Price Target on IDEXX Laboratories to $665 From $655 MT
May. 06 Jefferies Adjusts Price Target on IDEXX Laboratories to $792 From $785 MT
Apr. 28 UBS Adjusts Price Target on IDEXX Laboratories to $640 From $730, Maintains Neutral Rating MT
Apr. 27 Jefferies Adjusts Price Target on IDEXX Laboratories to $785 From $820, Maintains Buy Rating MT
Apr. 15 Citigroup Initiates IDEXX Laboratories at Neutral With $650 Price Target MT
Apr. 14 Leerink Partners Adjusts IDEXX Laboratories PT to $725 From $760, Maintains Outperform Rating MT
Mar. 31 Stifel Nicolaus Adjusts IDEXX Laboratories PT to $675 From $775, Maintains Buy Rating MT
Feb. 09 Piper Sandler Adjusts Price Target on IDEXX Laboratories to $750 From $775, Maintains Neutral Rating MT
Feb. 05 Barclays Adjusts Price Target on IDEXX Laboratories to $800 From $850, Maintains Overweight Rating MT
Feb. 04 Barclays Lowers Price Target on IDEXX Laboratories to $800 From $850 MT
Feb. 03 Jefferies Adjusts Price Target on IDEXX Laboratories to $820 From $830 MT
Feb. 03 UBS Adjusts IDEXX Laboratories PT to $730 From $750 MT
Feb. 03 Leerink Partners Adjusts Price Target on IDEXX Laboratories to $760 From $785 MT
Feb. 03 BTIG Adjusts Price Target on IDEXX Laboratories to $800 From $830 MT
Feb. 03 Rothschild & Co Redburn Adjusts Price Target on IDEXX Laboratories to $655 From $700 MT
Dec. 09 Barclays Initiates IDEXX Laboratories With Overweight Rating, $850 Price Target MT
Nov. 10 Piper Sandler Adjusts Price Target on IDEXX Laboratories to $775 From $700 MT
Nov. 04 UBS Adjusts Price Target on IDEXX Laboratories to $750 From $710, Maintains Neutral Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+34.31%
+21.69%
+21.49%
+33.56%
+59.76%
+22.98%
+9.31%
+28.07%
+9.49%
+41.14%
Average +28.18%
Weighted average by Cap. +28.10%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
517.75USD
Average target price
701.33USD
Spread / Average Target
+35.46%
High Price Target
805.00USD
Spread / Highest target
+55.48%
Low Price Target
470.00USD
Spread / Lowest Target
-9.22%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
Global
Quality
ESG MSCI
AAA
  1. Stock Market
  2. Stocks
  3. IDXX Stock
  4. Consensus IDEXX Laboratories, Inc.